Clinical Trial Update: Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating whether adding vildagliptin to metformin improves beta cell function and cardiovascular risk markers in patients with type …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: ikfe-CRO GmbH | Conditions: Diabetes Mellitus Type II | Phase 4 | Status: UNKNOWN